SCHEMBL25986509

SCHEMBL25986509

N=C(N)c1c(NN)n([C@@H]2O[C@H](CCO)[C@@H](O)[C@H]2O)c2ncnc(N)c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.69
HSPA8 P11142 5/20 0.58
CDK2 P24941 3/20 0.53
CDK1 P06493 2/20 0.53
CCNA2 P20248 2/20 0.53
CCNA1 P78396 2/20 0.53
CCNB1 P14635 1/20 0.53
CDK5 Q00535 2/20 0.48
CDK5R1 Q15078 1/20 0.48
HSPA5 P11021 2/20 0.44
NPC1 O15118 1/20 0.43
GALR3 O60755 1/20 0.43
S1PR4 O95977 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
S1PR1 P21453 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
PAX8 Q06710 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20141370 0.92 HIF1A (0.81) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL25986492 0.90 HIF1A (0.65) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141988 0.85 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL22111053 0.85 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL30131081 0.85 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL23950000 0.83 HIF1A (0.68) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL25986360 0.83 HSPA8 (0.82) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141359 0.82 HIF1A (0.75) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL12284814 0.82 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL22111064 0.82 HIF1A (0.81) HIF1AHSPA8CDK2CDK1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233591-A1 METHOD FOR TREATING POXVIRIDAE INFECTIONS OYAGEN, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233591-A1 METHOD FOR TREATING POXVIRIDAE INFECTIONS ITPA, VAC14, MAVS HIF1A 3831/4885HSPA8 1528/4885CDK2 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.